




已阅读5页,还剩21页未读, 继续免费阅读
版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
OsteoporosisACOG 2004; 50: 203-16. R4 Osteoporosis Systemic skeletal disease Microarchitectural deterioration of bone tissue with a resultant increase in fragility. 13-18 % of U.S. women over 50 years Another 37-50% have osteopenia Increase the risk of fracture Hip Fx. Morbidity and mortality 15-20% Thoracic spine Fx. Morbidity, including pain Deformity Loss of indepandence Reduce of cardiovascular, respiratory, digestive function. Osteoporosis is a largely preventable complication of menopause.Background Definition Pathophysiology Factors Affecting Bone Mass Screening MethodsDefinitionsAxial skeleton measurement of bone mineral density. Z score or T scores of DXA of lumbar spine or hip.Z score Based of standard deviation from the bone mineral density of a same sex, race, and age.T score Based on the mean peak bone mineral density of a normal young adult population.Definitions 1 SD decrease = 2 fold increase of Fx. Risk Peripheral bone T score Cannot used WHO classification. Used predict of fracture. Osteoporosis screening. In development.Pathophysiology Bone remodeling unit : osteoblast, osteoclast Cycle is divided into 4 phase Take several months to complete Resting Stem cell from BM are attracted to bone surface and differentiate into osteoclasts. Resorption Acid pH mineral dissolve , proteolytic enzymes digest the bone proteins. Reversal Osteoclast cease removing bone. Stem cell attracted to the bone surface, and differentiated into osteoblast. Formation Make new bone with protein matrix(osteoid). Protein matrix accounts for much of tensile strength. Mineral component provides compressional strength. Cytokine (interleukin 1, 3, 6, 11), growth factor, platelet derived GF, IGF-I,II modulate osteoclast and osteoblast function.PathophysiologyBone can be divided into 2 major type Cortical boneOuter shall75% of total bone mass Trabecular boneInternal supportSpongy, interlacing network.25% of total bone massMost of the volume in bone.Because of its larger surface and higher rate of turnover, it shows early bone loss, and first response to therapy.PathophysiologyBone mass peaks at age 30 years 0.4% lost per year after peak. 2% of cortical bone, 5% of trabecular bone loss per year for the 5-8 years after menopause. In recently menopause, excess bone loss is commonly caused by excessive osteoclast-mediated resorption. Later poatmenopausal, suppression of osteoblast activity and inadequate formation of bone play a major role of osteoporosisFactors Affecting Bone Mass Single largest factor is Genetic factor. Family history Caucasian and Asian women Mexican-American African-American Weight-bearing exercise stimulate osteoblastic activity. High dose of corticosteroid(7.5mg) chronic heparin thrapy(12,000-50,000) is associated with bone loss. Hyperthyroidism Factors Affecting Bone MassClinical Considerations and Recommendations When should screening for osteoporosis be initiated? Under what circumstances are screening tests other than DXA useful? Can lifestyle changes prevent osteoporosis and osteoporosis related fracture? Is there a role for estrogen and progestin for the prevention or treatment of osteoporosis? When estrogen therapy is discontinued, how should a woman be monitored for osteoporosis risk? Is other pharmacotherapy beneficial for the prevention and treatment of osteoporosis? Are complementary and alternative therapies beneficial for the prevention of osteoporosis? When should treatment for osteoporosis begin and how should patients be followed?When should screening for osteoporosis be initiated? Guidelines of testing bone mineral density All postmenopausal women aged 65yrs or older. Post menopausal women younger than 65yrs who have 1 or more risk factor All postmenopausal women with fracture to confirm the diagnosis of osteoporosis and determine disease severity. National Osteoporosis Foundation : postmenopausal women aged 50-60 with risk factors or 60-65yrs with or without R/F. Premenopausal women with certain disease or medical conditions For making decision about prevention therapy of early menopausal women. Without new risk factor, not be performed more frequently than every 2 years. Vertebral Fx. order, menopausal women bone mineral density test nonvertebral Fx.(hip or wrist) .Under what circumstances are screening tests other than DXA useful? Peripheral bone densinometry Less expensive, portable, reasonable precision, and low radiation exposure. Screening tools in the evaluation of bone loss, but cannot replace DXA scan for prediction of hip Fx. And the diagnosis of osteoporosis. Quantitative Ultrasonography Provides information on bone elasticity and structure in peripheral sites. Advantage : low cost and lack of radiation. Peripheral Quantitative Computed Tomography Ability to distinguish cortical form trabecular bone. Early and more precise assessment of skeletal change, due to quick change of trabecular bone More expensive and more radiation Less dataUnder what circumstances are screening tests other than DXA useful? Biochemical Makers of Bone Turnover Cannot diagnose osteoporosis, predict bone density or fracture risk. Useful to help identify women with high bone turnover. Assessment of theraputic response (earlier than bone mineral density change) Very expensive.Can lifestyle changes prevent osteoporosis and osteoporosis-related fracture? Weight-bearing exercise stimulate osteoblast to form new bone. Persist only when exercise is continued. For 22 months, 6.1% of bone density of lumbar vertebrae increase observed in postmenopausal women. Disease and sensory impairments that can cause falling should be treated. Medications, living environment should be monitored. Cessation of smoking, reducing alcohol intake Alcohol(7 oz or more per week) increase the risk for both fall and hip fracture and has detrimental effect on bone mineral density. Moderate alcohol is associated with increased mineral bone density. (it is not clear why this occur)Is there a role for estrogen and progestin for the prevention or treatment of osteoporosis? Conjugated equine estrogen(0.625 mg/d) with medroxyprogesterone acetate(2.5 mg/d) reduced the risk of hip and vertebral Fx by 34%, overall Fx by 24%. Lower dose combinations of conjugated equine estrogen(0.3 mg/d) with medroxyprogesterone acetate(2.5 mg/d) increased bone density 3.5-5.2% in postmenopausal(order than 65 yrs). Other study 0.3mg of oral esterified estrogens Transdermal 17B-estradiol 0.025-0.1 mg per day Optimal time to initiate therapy Not determined Believed work best in the first 5-10 years after menopause. A study shows order (mean 76 yrs old) women therapy increased bone density. Therapy discontinued, bone turn over and bone loss accelerated, then approaches that of not treated. Risk of long-term use Increase the risk of cardiovascular and breast cancer.When estrogen therapy is discontinued, how should a woman be monitored for osteoporosis risk?Same as early stage of menopause.Based on age and other risk factorIs other pharmacotherapy beneficial for the prevention and treatment of osteoporosis?2 categories Bisphosphonates (ie, alendronate, risendronate)Inhibit osteoclast activityBoth spine and hipReduce Fx. 30-50%Upper G-I S/E and very poor absorption(less then 1%) Take on empty stomach With only water Remain upright at least 30 min. No additional food or drink during this period. Used when established disease.Is other pharmacotherapy beneficial for the prevention and treatment of osteoporosis? Selective estrogen receptor modulators (SERMs) (ie, raloxifene, tibolone, tamoxifen) Mixed estrogenic and antiestrogenic property depending on tissue. Estrogen like effect on skeleton bone density and to reduce fracture without stimulating endometrial and breast tissue. Raloxifene Reduce 35-50% vertebral Fx. S/E vasomotor symptoms (hot flush, night sweat)- DVT Tibolone Reduce Fx risk Androgenic effect on sexual function Progestational effect on the endometrium. Tamoxifen Used as estrogen receptor positive breast ca. and for chemo prevention of breast ca. Reduce Fx risk . Increase vasomotor Sx. Stimulate endometrium. Incerase venous thrombosisIs other pharmacotherapy beneficial for the prevention and treatment of osteoporosis? Salmon calcitonin is available for osteoporosis treatment. S.C. inj. or nasal spray Reduce lumbar spine Fx(36%) at a dose 200U per day, but did not reduce hip Fx. Reduce bone turnover, but bone density change are small(1 %). Reduce bone pain of osteoporotic compression Fx. S/E : nausea, local inflammation(inj.), flush of face and hands, nasal irritation. Recombinant human PTH Increase trabecular bone density and connentivity. Use in case of failed response to other therapy or very severe disease. Reduce vertebral Fx 53-54%. Expensive and needs daily injection. PTH is significantly reduced when co-administration with bisphosphonates; therefore, they should not be combined. Fluoride increase bone brittleness and propensity to fracture. Testosterone effect is not clear.Is other pharmacotherapy beneficial for the prevention and treatment of osteoporosis? Combinations of Antiresorptive Therapies Addition of progesterones, addition of androgens can have additive effect on bone mineral density. Risedronate, alendronate and raloxifen bone mineral density (1-3%) . fracture protection . Calcium and vit.D should be considered adjuvant therapy for individual.Are complementary and alternative therapies beneficial for the prevention of osteoporosis? Isoflavones (a class of phytoestrogens found in rich supply in soybeans and red clover) studies has not demonstrated a reliable positive effect on bone density, bone turnover marker, or fracture risk in woman with osteoporosisWhen should treatment for osteoporosis begin and how should patients be followed?T score 1 SD decrease = 10-12% change in bone mineral density.Low risk of fracture in young women with osteopenia High cost long term side effect led to suggest withholding treatment until certain theraputic threshold have been reached.The National Osteoporosis Foundation T score -2 without risk factor T score -1.5 with risk factorWhen should treatment for osteoporosis begin and how should patients be followed?Monitoring of treatment requires central bone densinometry. Precision : 2-3% Repeat DXA testing untreated post menopausal per 3-5 yearsTreatment monitor 2 .4-5% mineral density loss .Summary of Recommendations Recommendations based on good and consistent scientific evidence (Level A) Treatment should be initiated to reduce fracture risk in postmenopausal women who have experienced a fragility or low-impact fracture. T scores less than -2 by central DXA in the absence of risk factor and less than -1.5
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 2024年初中数学考前冲刺复习方案
- 零售超市商品陈列标准规范
- 新零售业智能客服系统方案设计与应用
- 小学三年级体育教学活动案例
- 农产品动态平衡干燥技术创新创业项目商业计划书
- 耐磨齿轮表面处理技术企业制定与实施新质生产力项目商业计划书
- 精密滚珠丝杠副制造企业制定与实施新质生产力项目商业计划书
- 宠物主题乐园创新创业项目商业计划书
- 软件开发项目需求文档写作技巧
- 项目投资分红权益协议标准文本
- 养老院护理员的岗前培训
- 微生物检验技能-细菌的生化试验
- 2025年1月上海市春季高考模拟英语试卷(含答案解析)
- 中国慢性阻塞性肺疾病基层诊疗指南(2024年)解读
- 2024年代还款三方协议书模板范本
- 2024-2025学年广东省深圳市南山育才集团九年级(上)期中语文试卷
- 2024-2025学年四年级上册数学青岛版期中模拟检测试题(1~4单元)
- 外研版(2024)七年级上册 Unit 2 More than fun练习(含答案)
- 1.1+生命之歌高中音乐粤教花城版(2019)必修音乐鉴赏音乐鉴赏
- 职业技术学院智能物流技术专业人才培养方案
- 1.1 坚持改革开放(课件) 2024-2025学年九年级道德与法治上册 (统编版2024)
评论
0/150
提交评论